Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Common Equity (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Common Equity for 11 consecutive years, with $715.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 38.13% year-over-year to $715.2 million, compared with a TTM value of $715.2 million through Dec 2025, up 38.13%, and an annual FY2025 reading of $715.2 million, up 38.13% over the prior year.
  • Common Equity was $715.2 million for Q4 2025 at Spyre Therapeutics, up from $455.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $715.2 million in Q4 2025 and bottomed at -$245.4 million in Q3 2023.
  • Average Common Equity over 5 years is $196.9 million, with a median of $121.4 million recorded in 2021.
  • The sharpest move saw Common Equity tumbled 463.26% in 2023, then soared 352.48% in 2024.
  • Year by year, Common Equity stood at $83.9 million in 2021, then tumbled by 40.07% to $50.3 million in 2022, then surged by 265.8% to $184.0 million in 2023, then surged by 181.39% to $517.8 million in 2024, then soared by 38.13% to $715.2 million in 2025.
  • Business Quant data shows Common Equity for SYRE at $715.2 million in Q4 2025, $455.1 million in Q3 2025, and $455.8 million in Q2 2025.